BIFIDOBACTERIUM LONGUM BB536: MULTIFUNCTIONAL HUMAN BIFIDOBACTERIA PROBIOTIC
Kondo J, Xiao JZ, Shirahata A, Baba M, Abe A, Ogawa K & Shimoda T. (2013). Modulatory effects of Bifidobacterium longum BB536 on defecation in elderly patients receiving enteral feeding. World J Gastroenterol. 19(14): 2162-2170.
IMMUNOMODULATION
Intake of BB536 reduces the incidence of influenza and fever in elderly during the 14 weeks experimental study.
BIFIDOBACTERIUM BREVE B3: NEW STRAIN FOR HEALTHY BODY WEIGHT AND METABOLISM
Intake of B3 for 3 months reduced body fat and improved blood lipid profile
SOURCE
ANTI-INFECTION
Children 2-6 years old took BB536 for 10 months reduced upper respiratory tract infection.
- Sore throat duration reduced 46.1%
- Fever duration reduced 27.8%
- Runny nose reduced 13.2%
- Cough reduced 16.3%
SOURCE
Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, Iwatsuki K, Kokubo S, Togashi H, Enomoto K & Enomoto T. (2006). Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese Cedar Pollinosis during the pollen season. A randomized double-blind placebo-controlled trial. J Investig Allergol Clin Immunol. 16(2): 86-93.
Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, Iwatsuki K, Kokubo S, Togashi H, Enomoto K & Enomoto T. (2006). Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese Cedar Pollinosis during the pollen season. A randomized double-blind placebo-controlled trial. J Investig Allergol Clin Immunol. 16(2): 86-93.
Percent body fat and body fat mass and were significantly lower in the B-3 group (0.7% and 0.6kg respectively) than in the placebo group after 8 and 12 weeks of consumption (p<0.05), without lifestyle and diet change.
BIFIDOBACTERIUM BREVE B3: NEW STRAIN FOR HEALTHY BODY WEIGHT AND METABOLISM
Intake of B3 for 3 months reduced body fat and improved blood lipid profile
Minami J, Iwabuchi N, Tanaka M, Yamauchi K, Xiao JZ, Abe F & Sakane N. (2018). Effects of Bifidobacterium breve B3 on body fat reductions in pre-obese adults: A randomized, double-blind, placebo-controlled trial. Bioscience of Microbiota, Food and Health. 37(3): 67-75.
Lau ASY, Yanagisawa N, Hor YY, Lew LC, Ong JS, Chuah LO, Lee YY, Choi SB, Rashid F, Wahid N, Sugahara H, Xiao JZ & Liong MT. (2018). Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Beneficial Microbes. 9(1): 61-70.
Consumption of B3 improve body composition and suppress inflammation
Body weight, fat mass, body fat percentage, Body mass index (BMI) and waist-hip ratio lowered after intake of B3 for 4 weeks, without lifestyle and diet change.
Lau ASY, Yanagisawa N, Hor YY, Lew LC, Ong JS, Chuah LO, Lee YY, Choi SB, Rashid F, Wahid N, Sugahara H, Xiao JZ & Liong MT. (2018). Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Beneficial Microbes. 9(1): 61-70.
hCRP level was lowered after intake of B3 for 12 weeks.
DID YOU KNOW?
C-reactive protein (CRP) is a marker for infection or inflammation while High sensitivity C-reactive protein (hCRP) can help determine the risk of cardiovascular diseases.
Lau ASY, Yanagisawa N, Hor YY, Lew LC, Ong JS, Chuah LO, Lee YY, Choi SB, Rashid F, Wahid N, Sugahara H, Xiao JZ & Liong MT. (2018). Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Beneficial Microbes. 9(1): 61-70.
Lau ASY, Yanagisawa N, Hor YY, Lew LC, Ong JS, Chuah LO, Lee YY, Choi SB, Rashid F, Wahid N, Sugahara H, Xiao JZ & Liong MT. (2018). Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Beneficial Microbes. 9(1): 61-70.
Lau ASY, Yanagisawa N, Hor YY, Lew LC, Ong JS, Chuah LO, Lee YY, Choi SB, Rashid F, Wahid N, Sugahara H, Xiao JZ & Liong MT. (2018). Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Beneficial Microbes. 9(1): 61-70.
Lau ASY, Yanagisawa N, Hor YY, Lew LC, Ong JS, Chuah LO, Lee YY, Choi SB, Rashid F, Wahid N, Sugahara H, Xiao JZ & Liong MT. (2018). Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Beneficial Microbes. 9(1): 61-70.
What is metabolic syndrome?
- Metabolic syndrome is a group of conditions include obesity, high blood pressure, high blood sugar and high cholesterols that all together may increase the risk of heart diseases, diabetes, stroke and other diseases.
Minami J, Kondo S, Yanagisawa N, Odamaki T, Xiao JZ, Abe F, Nakajima S, Hamamoto Y, Saito S & Shimoda T. (2015). Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial. Journal of Nutritional Science. 4(17): 1-7.
Minami J, Kondo S, Yanagisawa N, Odamaki T, Xiao JZ, Abe F, Nakajima S, Hamamoto Y, Saito S & Shimoda T. (2015). Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial. Journal of Nutritional Science. 4(17): 1-7.
HUMAN MILK OLIGOSACCHARIDES (HMOs) 2’FUCOSYLLACTOSE: FOR DIGESTIVE HEALTH, IMMUNITY, BRAIN HEALTH AND MANY MORE
DID YOU KNOW?
Human milk oligosaccharides or 2’ Fucosyllactose is the third most abundant component in human breast milk, after lactose & lipid. It is the key component or factor that bringing wide health benefits to infants, as well as adults. It also acts as a prebiotic to support the growth of Bifidobacterium.
Minami J, Odamaki T, Hashikura N, Abe F & Xiao JZ. (2016). Lysozyme in breast milk is a selection factor for bifidobacterial colonisation in the infant intestine. Beneficial Microbes. 7(1):53-60.